Generic antibiotic drugs: Is effectiveness guaranteed?

Medecine et Maladies Infectieuses

Volumn 42, Issue 4, 2012, Pages 141-148

  Gauzit, R ^a   Lakdhari, M ^a  

^a HÔTEL DIEU   (France)

Author keywords

Antibiotics; Branded drugs; Effectiveness; Generic drugs; Therapeutic equivalence

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIMETHATE; COLISTIN; GENERIC DRUG; GENTAMICIN; IMIPENEM; ITRACONAZOLE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL EFFECTIVENESS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MARKETING; DRUG SCREENING; DRUG TOLERABILITY; ESCHERICHIA COLI INFECTION; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INFECTION; INFECTION PREVENTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTOPERATIVE INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEPTIC SHOCK; SPLEEN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; DRUG SUBSTITUTION; DRUG TOXICITY; DRUG UTILIZATION; DRUGS, GENERIC; EUROPEAN UNION; HEALTH POLICY; HUMANS; MARKETING; MEDICATION ADHERENCE; MICE; MICROBIAL SENSITIVITY TESTS; THERAPEUTIC EQUIVALENCY;

EID: 84861182328     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.10.013     Document Type: Review

References (30)

1. Berg M.J., Gross R.A., Tomaszewski K.J., Zingaro W.M., Haskins L.S. Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures. Neurology 2008, 71:525-530.
2. Kesselheim A.S., Misono A.S., Lee J.L., Stedman M.R., Brookhart M.A., Choudhry N.K., et al. Clinical equivalence of generic and branded drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008, 300:2514-2526.
3. WHO/DMP/RGS. Marketing authorization of pharmaceutical products with spécial reference to multisource (generic) products: a manual for a drug regulatory authority. 1998.
4. European Medicals Agency. Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf.
5. Nightingale C.H. A survey of the quality of generic clarythromycin products from 18 countries. Clin Drug Invest 2005, 25:135-152.
6. Snyman J.R., Schoeman H.S., Grobush M.P., Henning M., Rabie W., Hira M., et al. Generic versus non-generic formulation of extended-release of clarithromycin in patients with community-acquired respiratory tract infection: a prospective randomized, comparative, investigator-blind multicenter study. Clin Drug Invest 2009, 29:266-274.
7. Del Tacca M., Pasqualetti G., Di Paolo A., Virdis A., Massimetti G., Gori G., et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol 2009, 68:34-42.
8. Cohen R., de la Rocque F., Lecuyer A., Wollner C.S., Bodin M.J., Wollner A. Study of the acceptability of antibiotic syrups, suspensions and oral solutions prescribed to pediatric outpatients. Eur J Pediatr 2009, 168:851-857.
9. Wollner A, Lécuyer A, de la Rocque F, Sedletzki G, Derkx V, Boucherat M, et al. Acceptability, compliance and schedule of administration of oral antiobiotics in outpatient children. Arch Pediatr 2011 [Epub ahead of print].
10. Guillemot D., Carbon C., Balkau B., Geslin P., Lecoeur H., Vauzelle-Kervroëdan F., et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998, 279:365-370.
11. Pasqualotto A.C., Denning D.W. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Intern J Antimicob Agents 2007, 30:93-94.
12. Lambert P.A., Conway B.R. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003, 15:357-368.
13. Wetterich U., Mutschler E. Quality of cefotaxime sodium preparations. Arzneimittelforschung 1995, 45:74-80.
14. He H, Li JC, Jacob J, Chen G, Lee HJ, Tsuji BT, et al. Pharmacokinetics (PK) of different brands of colistin methanesulfonate (CMS) in rats. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, USA; 2010 [abstract A1-662].
15. Schito G.C., Keenan M.H. Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother 2005, 17(Suppl. 2):33-40.
16. Fujimura S., Fuse K., Tafane H., Nakano Y., Gomi K., Kikushi T., et al. Antibacterial effects of branded teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus. J Infect Chemother 2011, 17:30-33.
17. Moet G.J., Watters A.A., Sader H.S., Jones R.N. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagn Microbiol Infect Dis 2009, 65:319-322.
18. Rodriguez C.A., Agudelo M., Zuluaga A.F., Vesga O. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect Dis 2010, 10:153. doi:10.1186/1471-2334-10-153.
19. Zuluaga A.F., Agudelo M., Rodriguez C.A., Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin Pharmacol 2009, 9:1. doi:10.1186/1472-6904-9-1.
20. Zuluaga A.F., Agudelo M., Cardeno J.J., Rodriguez C.A., Vesga O. Determination of therapeutic equivalence of generic products of gentamicin in neutropenic mouse thigh infection model. PLoS One 2010, 5(5):e10744.
21. Vesga O., Agudelo M., Salazar B.E., Rodriguez C.A., Zuluaga A.F. Generic vancomycin products fails in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010, 54:3271-3279.
22. Agudelo M, Franco S, Cardeno JJ, Roncancio GA, Robledo JM, Alvarez MF, et al. Therapeutic failure of a bioequivalent generic product of imipenem against Pseudomanas aeruginosa in a murine meningoencephalitis model. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, USA; 2010 [abstract A1-1385].
23. Tansuphasawadikui S., Simarol S., Chantarothorn S., Nuntacit K., Mansakui W., Yomtem K., et al. Therapeuticeffectiveness of a generic versus original meropenem in serious infections. J. Med Assoc Thai 2011, 94:172-178.
24. Angkasekwinai N., Werarak P., Chaiyasoot K., Tamlikitkui V. Monitoring effectivness and safety of genric formulation of meropenem for treatment of infections at Siriraj hospital. J. Med Assoc Thai 2011, 94(Suppl. 1):S217-S224.
25. Piyasirisilp S., Premprawat W., Tamlikitkui V. Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Sirijaj hospital. J. Med Assoc Thai 2010, 93(Suppl. 1):S117-S125.
26. Mastoraki E., Michalopoulos A., Kriaras I., Mouchtouri E., Falagas M., Karatza D., et al. Incidence of postoperative infections in patients under going coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect 2008, 56:35-39.
27. Gerlinger MP, Rousselot P, Rigaudeau S, Billon C, Touratier S, Castaigne S et al. Pipéracilline-tazobactam et faux positifs en antigène galactomannane. 12e Journées nationales d'infectiologie (JNI). Toulouse, France; 2011 [abstract G-01].
28. Monnet Dl, Ferech M., Frimodt-Moller N., Goossens H. The more antimicrobial trade names, the more consumption of antibacterials: A european study. Clin Infect Dis 2005, 41:114-117.
29. Jensen U.S., Muller A., Brandt C.T., Frimodt-Moller N., Hammerum A.M., Monnet DL Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother 2010, 65:1281-1286.
30. Kaier K., Frank U., Meyer E. Economic incentives for the (over)-prescription of broad-spectrum antimicrobials in german ambulatory care. J Antimicrob Chemother 2011, 66:1656-1658.